Search details
1.
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Oncologist
; 24(5): 648-656, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30591549
2.
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Oncologist
; 23(3): 328-336, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29317551
Results
1 -
2
de 2
1
Next >
>>